Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Pharm Exec2d
Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
pharmaphorum2d
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
FierceBiotech3d
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...
Newton biotech gets $200M for rare muscle disease drug
Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...
Healio4d
Silica dust, heavy metal, solvents may contribute to myositis with lung involvement
Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...